Ipsen Archives

Podcast 1 Dec 2023

Ipsen drug gives hope for liver disease patients

On the podcast this week, we are looking at recent advances in treating certain liver diseases. Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen, and she discusses a breakthrough treatment for primary biliary cholangitis and cholestatic liver disease. What is primary biliary cholangitis? Primary biliary […]

December 1, 2023

News and Trends 12 Aug 2021

European Biotechs Fire up Deals to Develop Parkinson’s Treatments

Last month, European biotechs Ipsen and AC Immune announced multi-million euro deals to acquire or license treatments for Parkinson’s disease. For some experts, this increasing interest in the brain disease with the fastest growing prevalence is long overdue. In July, Swiss company AC Immune bought assets and intellectual property for investigational Parkinson’s vaccines valued at […]

August 12, 2021 - 4 minutesmins - By Anita Chakraverty

News and Trends 31 Mar 2020

Ipsen Resumes Phase III Testing for Rare Disease Drug and Abandons Pediatric Trial

The French pharmaceutical company Ipsen has restarted the dosing of its treatment for a rare bone disease in a phase III trial after obtaining questionable interim results. At the same time, the company has terminated a phase II trial of the same drug in pediatric patients with a different bone disorder following a partial clinical […]

March 31, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 8 Jun 2016

12 European Biotechs which ‘stole the show’ at World most Important Cancer Meeting

Pharma and Biotech from every corner flocked to Chicago for the beginning of June. Why? It’s where one of the biggest oncology events happens – the ASCO Annual Meeting 2016. Shortly after the AACR annual meeting (with presentations from several European Biotechs), it’s time for the ASCO annual meeting. Hosted by the American Society of Clinical […]

June 8, 2016 - 7 minutesmins - By Denise Neves Gameiro

exelixis ipsen cancercabozantinib renal liver endometrial nsclc

News and Trends 1 Mar 2016

French Ipsen closes €700M deal for Californian Cancer Drug

Ipsen is paying Exelixis $200M upfront, plus $545M in future milestones to acquire commercialization rights for a multi-organ cancer candidate outside US, Canada and Japan. California-based Exelixis has found an European partner to license the small molecule drug, cabozantinib. Ipsen, a French biotech group, will have comercialization rights for cabozantinib worldwide, except in the US and […]

March 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 2 Jun 2015

After Failing Phase III, Active Biotech is back to square one

Unfortunately, the Biotech world is not only composed of success stories. Active Biotech, a Swedish company focused on developing treatments for neurodegenerative diseases and cancer. The company, engaged with Ipsen, discontinued a Phase III study and is currently discovering the consequences of this failure the hard way. Active Biotech’s business model, like many small red biotechs, is based on partnering with […]

June 2, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 25 Feb 2015

Ipsen buys an option to Acquire Canbex

Canbex, a spin-off of University College London (UCL) that raised a Series A financing of €2.8M in 2013 from MS Ventures, may become part of Ipsen. The French giant payed €6M upfront for the option to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment […]

February 25, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us